SCHEMBL4089492

SCHEMBL4089492

COc1ccc2cc(-c3n[nH]c4ccc(-c5nc(CN)n[nH]5)cc34)ccc2c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TTK P33981 3/20 0.46
ITK Q08881 6/20 0.43
GRK6 P43250 1/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
LRRK2 Q5S007 1/20 0.41
KDM4E B2RXH2 1/20 0.40
BTK Q06187 1/20 0.40
HTR2A P28223 1/20 0.40
HTR2C P28335 1/20 0.40
HTR2B P41595 1/20 0.40
FLT3 P36888 3/20 0.40
PRKAG1 P54619 1/20 0.40
PRKAA1 Q13131 1/20 0.40
PRKAB1 Q9Y478 1/20 0.40
LOXL2 Q9Y4K0 1/20 0.40
DCUN1D1 Q96GG9 1/20 0.39
TEK Q02763 1/20 0.39
PLK4 O00444 1/20 0.39
CHEK1 O14757 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13811890 0.89 GRK6 (0.46) TTKITKGRK6NPC1RAB9A
SCHEMBL13812021 0.83 TTK (0.39) TTKITKGRK6NPC1RAB9A
SCHEMBL4084647 0.83 CLK2 (0.46) TTKITKRAB9ALRRK2KDM4E
SCHEMBL4085679 0.82 LRRK2 (0.42) TTKITKGRK6LRRK2HTR2A
SCHEMBL13812149 0.80 LRRK2 (0.39) TTKITKGRK6LRRK2HTR2A
SCHEMBL4084381 0.80 GSK3B (0.46) ITKGRK6LRRK2CDK2
SCHEMBL13812153 0.80 GSK3B (0.47) TTKLRRK2ABL1CDK2
SCHEMBL13890795 0.79 GRK6 (0.37) TTKITKGRK6NPC1RAB9A
SCHEMBL4094963 0.79 CYP1A2 (0.49) TTKITKGRK6NPC1RAB9A
SCHEMBL13811889 0.79 HRH3 (0.43) ITKLRRK2KDM4EABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2065383-A1 Indazole compounds and methods of use thereof as protein kinase inhibitors Signal Pharmaceuticals, Inc. (US) 2009-06-03 EP disclosed
EP-2065383-A1 Indazole compounds and methods of use thereof as protein kinase inhibitors Signal Pharmaceuticals, Inc. (US) 2009-06-03 EP disclosed
US-20090099178-A1 INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF BHAGWAT SHRIPAD S 2009-04-16 US disclosed
US-20090099178-A1 INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF BHAGWAT SHRIPAD S 2009-04-16 US disclosed
US-20090099178-A1 INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF BHAGWAT SHRIPAD S 2009-04-16 US disclosed
EP-1692128-A1 INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF AS PROTEIN KINASE INHIBITORS Signal Pharmaceuticals LLC (US) 2006-08-23 EP disclosed
US-20060004043-A1 Indazole compounds and methods of use thereof BHAGWAT SHRIPAD S 2006-01-05 US disclosed
WO-2005051942-A1 INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF AS PROTEIN KINASE INHIBITORS SIGNAL PHARMACEUTICALS, LLC (US) 2005-06-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099178-A1 INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF WNT3, WNT3A, WNK3 TTK 401/4885ITK 74/4885GRK6 762/4885
US-20060004043-A1 Indazole compounds and methods of use thereof WNT3, WNT3A, WNK3 TTK 377/4885ITK 77/4885GRK6 760/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.